Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple ‘Centers of Excellence’ At FDA Could Create Review Inefficiencies – Jenkins

Executive Summary

In an interview, US FDA’s outgoing head of new drug review cautions against duplicating the agency's Oncology Center of Excellence model across multiple therapeutic areas, advocating for a more "balanced portfolio" in structuring review operations.

Advertisement

Related Content

Ostroff: Administration Coming Up To Speed On Planned FDA Guidances
Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?
FDA Oncology Center Of Excellence Coming, Moonshot Or Not

Topics

Advertisement
UsernamePublicRestriction

Register

MT104244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel